[go: up one dir, main page]

TN2023000295A1 - Oral dosage forms of ibrutinib - Google Patents

Oral dosage forms of ibrutinib

Info

Publication number
TN2023000295A1
TN2023000295A1 TNP/2023/000295A TN2023000295A TN2023000295A1 TN 2023000295 A1 TN2023000295 A1 TN 2023000295A1 TN 2023000295 A TN2023000295 A TN 2023000295A TN 2023000295 A1 TN2023000295 A1 TN 2023000295A1
Authority
TN
Tunisia
Prior art keywords
ibrutinib
dosage forms
oral dosage
acidifying agent
cancers
Prior art date
Application number
TNP/2023/000295A
Inventor
Shahin Fesharaki
Mahmoud Ghannam
Mohammad Hreebat
Ahmad Mohammad
Original Assignee
Hikma Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hikma Pharmaceuticals Usa Inc filed Critical Hikma Pharmaceuticals Usa Inc
Publication of TN2023000295A1 publication Critical patent/TN2023000295A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Stable and bioavailable oral dosage forms of ibrutinib, the dosage forms comprising ibrutinib and an acidifying agent. The dosage forms can further comprise a binder, such as sodium alginate, a surfactant, a lubricant, a filler and/or a disintegrant. Methods of treating cancers, particularly blood cancers, and graft versus host disease comprising administering to a patient in need thereof a dosage form comprising ibrutinib and an acidifying agent.
TNP/2023/000295A 2021-06-10 2021-06-10 Oral dosage forms of ibrutinib TN2023000295A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/036712 WO2022260667A1 (en) 2021-06-10 2021-06-10 Oral dosage forms of ibrutinib

Publications (1)

Publication Number Publication Date
TN2023000295A1 true TN2023000295A1 (en) 2025-07-02

Family

ID=76731098

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP/2023/000295A TN2023000295A1 (en) 2021-06-10 2021-06-10 Oral dosage forms of ibrutinib

Country Status (3)

Country Link
MA (1) MA63498A1 (en)
TN (1) TN2023000295A1 (en)
WO (1) WO2022260667A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117064862A (en) * 2023-04-10 2023-11-17 山东新时代药业有限公司 Ibutenib enteric-coated tablet and preparation method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2529622T3 (en) 2006-09-22 2018-07-31 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
TR201010618A2 (en) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut An oral dosage form comprising imatinib and the manufacture of an oral dosage form
KR20220093389A (en) 2012-06-04 2022-07-05 파마싸이클릭스 엘엘씨 Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103694241A (en) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Novel crystal form A of PCI-32765 and preparation method thereof
WO2016105582A1 (en) * 2014-12-24 2016-06-30 Nunn Philip A Compositions for ileo-jejunal drug delivery
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
US20160287594A1 (en) * 2015-04-06 2016-10-06 Janssen Pharmaceutical Nv Compositions Containing Ibrutinib
CZ2016196A3 (en) * 2016-04-06 2017-10-18 Zentiva, K.S. Solid forms of Ibrutinib
US20190224204A1 (en) * 2016-08-19 2019-07-25 Cipla Limited Pharmaceutical compositions of ibrutinib
CN111000806A (en) * 2018-10-07 2020-04-14 威海云睿信息科技有限公司 Ibrutinib tablet composition
KR20200127888A (en) * 2019-05-03 2020-11-11 보로노이 주식회사 Oral pharmaceutical compositions in the form of solid formulation comprising ibrutinib or a pharmaceutically acceptable salt thereof and processes for preparing the same

Also Published As

Publication number Publication date
WO2022260667A1 (en) 2022-12-15
MA63498A1 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
PA8588601A1 (en) COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
NZ606825A (en) Methods and compositions for treating complement-associated disorders
RU2012148710A (en) ORGANIC COMPOUND FOR USE IN TREATMENT OF LIVER CANCER
EP4582105A3 (en) Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
NZ702801A (en) Treatment of sanfilippo syndrome type b
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
NZ604029A (en) Methods of treating bladder cancer
BRPI0513200A (en) use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
NZ709704A (en) Protein formulations and methods of making same
UA92453C2 (en) Carbostyril derivatives and mood stabilizers for treating mood disorders
CY1112184T1 (en) PYRIDOXAMINE FOR USE IN TREATMENT OF DIABETIC Nephropathy in Type II Diabetes
CN1859918B (en) Application of hyaluronic acid in preparing medicine for treating acute and overstrain sprain and strain
MX2022014199A (en) Uses and formulations of cannabinoids.
EP4316589A3 (en) Treatment of patients with classic fabry disease
MXPA04005420A (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
MX2024011142A (en) Treatment of cutaneous neurofibromas with mirdametinib.
TN2023000295A1 (en) Oral dosage forms of ibrutinib
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections
MX2024001832A (en) Oral composition comprising a mdm2-antagonist for cancer therapy.
BR112012011316A2 (en) tivozanib and temsirolimus in combination
IL159770A0 (en) Calcium salts with cytotoxic activity
MX2025000408A (en) Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations
Connett et al. A smoking cessation program plus inhaled ipratropium improved survival in smokers with asymptomatic airway obstruction/COMMENTARY
ZA202200330B (en) Pharmaceutical composition of imatinib